Kylo-0603

KYLO-0603 is an orally active, selective THR-β agonist (EC50: 31.07 nM) . KYLO-0603 has significant activity in lowering serum cholesterol and low-density lipoprotein cholesterol. KYLO-0603 upregulates the expression of THR-regulated genes (including iodothyronine deiodinase 1 (Dio1), malic enzyme 1 (Me1), and thyroid hormone response (Thrsp) gene) and inhibits the expression of inflammatory and fibrotic genes (low-density lipoprotein receptor (LDL-R) gene) by activating THR-β receptors. KYLO-0603 can be used to treat metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis research[1].

Product Specifications

CAS Number

[2661053-09-2]

UNSPSC

12352005

Target

Interleukin Related; LDLR; Thyroid Hormone Receptor

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Field of Research

Infection; Metabolic Disease

Smiles

O=C(CCOCC(COCCC(NCCCCCCO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O)=O)(NC(CCCCCNC(COC2=CC(C)=C(CC3=CC(C(C)C)=C(O)C=C3)C(C)=C2)=O)=O)COCCC(NCCCCCCO[C@@H]4O[C@H](CO)[C@H](O)[C@H](O)[C@H]4NC(C)=O)=O)NCCCCCCO[C@@H]5O[C@H](CO)[C@H](O)[C@H](O)[C@H]5NC(C)=O